Format

Send to

Choose Destination
Anticancer Res. 2014 Feb;34(2):1037-45.

Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.

Author information

1
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea. jh21.jang@samsung.com, chulwon1.jung@samsung.com.

Abstract

BACKGROUND:

Acute myeloid leukemia (AML) cases with t(8;21) or inv(16) have a favorable outcome, but the associated prognoses are heterogeneous and complicated by additional molecular aberrations.

PATIENTS AND METHODS:

Between January 2000 to December 2010, 67 patients were diagnosed with t(8;21) or inv(16) AML. We collected cytogenetic variables and analyzed treatment outcomes.

RESULTS:

Among 67 patients, 51 (7.8%) had t(8;21) AML and 16 (2.4%) had inv(16) AML. Thrombocytopenia, and a high percentage of blasts in the peripheral blood and bone marrow were associated with poor overall survival. Twenty-five (49.0%) patients with t(8;21) had an additional chromosomal abnormality, while only six (37.5%) patients with inv(16) AML had a secondary chromosomal abnormality. The most common chromosomal abnormalities were deletion of the Y or X sex chromosomes.

CONCLUSION:

Deletion of the Y chromosome may be a favorable prognostic factor in patients with core binding factor-positive AML.

KEYWORDS:

Core-binding factor-positive AML; prognostic factor

PMID:
24511052
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center